Strides Arcolab is currently trading at Rs 401.10, up by 6.35 points or 1.61% from its previous closing of Rs 394.45 on the BSE.
The scrip opened at Rs 399.10 and has touched a high and low of Rs 407.80 and Rs 397.10 respectively. So far 4536 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 438.85 on 12-Jan-2011 and a 52 week low of Rs 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs 409.50 and Rs 387.20 respectively. The current market cap of the company is Rs 2341.92 crore.
The promoters holding in the company stood at 28.43% while Institutions and Non-Institutions held 52.90% and 18.68% respectively.
Strides Arcolab, the Indian drug maker is likely to sell its Australian branded-generics unit, Ascent Pharmahealth. The company is also considering the divestment of other businesses such as softgel and anti-retro viral drug manufacturing, as the drug maker wants to focus on specialty injectables. US investment bank Jefferies and Co is advising Strides Arcolab for the divestments.
Ascent Pharmahealth is one of the largest branded generic drugmakers in Australia, with 13% market share. It also has a significant presence in Singapore, Thailand and Vietnam. In 2010, the business had sales of $140 million.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: